LINCOLNSHIRE – Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry. The acquisition of this FDA-approved facility in Pleasant Prairie, Wisconsin will further expand Lilly’s global parenteral (injectable) product manufacturing network and support increased demand for the …
LA – For more information about Lilly’s COVID-19 therapies authorized for emergency use, contact the Lilly COVID Hotline at 1-855-LillyC19 (1-855-545-5921). Lilly continues to closely monitor the COVID-19 pandemic and its global impact. As this is an evolving topic, Lilly will include relevant announcements and information on this page. If the COVID-19 pandemic has impacted your ability to afford or access …
INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell malignancies. These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, continue to …
INDIANAPOLIS – Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in The Journal of the American Medical Association (JAMA). Zepbound met the primary endpoint of mean percent change in body weight, and all key secondary endpoints …
INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) today announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of 2024. Gateway Labs is Lilly’s shared innovation accelerator that provides participating companies with state-of-the-art lab space and unique access to Lilly scientists, researchers and executives, as well as exposure to Lilly’s functional and scientific expertise. This will be the company’s third Gateway Labs location, with additional …
